Atturos
4 Projects, page 1 of 1
Open Access Mandate for Publications assignment_turned_in Project2016 - 2016 AtturosAtturosFunder: EC Project Code: 711761Overall Budget: 71,429 EURFunder Contribution: 50,000 EURIn Europe over 400,000 (US >250,000, globally >1M) men are diagnosed with prostate cancer every year and well over half will have intermediate to low risk disease. The vast majority of these men would benefit from active surveillance (AS) - monitoring of disease progression before treatment. But most are treated by surgery, radiation or drugs because existing diagnostic tools do not adequately support the AS vs. treatment decision. For those men on AS the tests do easily allow long term repeated monitoring. The over-treatment of prostate cancer is a widely acknowledged and serious issue: the side effects of treatment are often worse than the disease itself and impact negatively on quality of life. We have discovered, developed and patented a blood protein signature that can discriminate between disease that remains confined to the prostate or has spread beyond it. This multiplexed protein signature, the OCProDx test, has the capacity to support at least three key patient decisions. i) for men newly diagnosed with prostate cancer: the decision between AS and treatment; ii) for men on AS: whether to treat or not, and iii) for those to be treated: which treatment may be the best option. The OCProDx test, will be licensed to a newly founded UCD Spin out company 'Atturos’. The market size is very large, the need significant and the estimated gross profit margin very attractive. We believe there is a compelling opportunity to grow Atturos to develop OCProDx within a commercial setting and deliver it to market. In so doing, Atturos will grow rapidly to create high value EU employment opportunities that will be global in reach. Well-resourced laboratory based studies are currently underway to consolidate the technical performance of OCProDx and validate its clinical performance. In this proposal we seek to engage with key external consultants to develop and produce a detailed business plan for Atturos to commercialise and monetise OCProDx.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::0c8a21ade4daee4bf0fa364808e76459&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::0c8a21ade4daee4bf0fa364808e76459&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications and Research data assignment_turned_in Project2019 - 2024 CYPROTEX DISCOVERY LIMITED, UNIVERSITA DEGLI STUDI DI PARMA, Atturos, UM, ULB +4 partnersCYPROTEX DISCOVERY LIMITED,UNIVERSITA DEGLI STUDI DI PARMA,Atturos,UM,ULB,UCD,CNR,ARTTIC,PreSens Precision Sensing (Germany)Funder: EC Project Code: 825745Overall Budget: 5,655,090 EURFunder Contribution: 5,655,090 EURSCREENED will develop 3 different three-dimensional (3D) in vitro assays based on rodent and human thyroid cell constructs. At different level of anatomical complexity, these assays will increasingly mimic the structure and function of the native thyroid gland, ultimately achieving the replication of its vascular anatomy and morphogenetic characteristics: 1) a 3D organoid based on stem-cell derived thyroid cells, 2) a decellularized scaffold able to reproduce the biological composition of a native thyroid, repopulated by the 3D organoids, and 3) a bioprinted construct with the 3D organoids able to mimic the spatial and geometrical architecture of a native thyroid. These 3D assays will be hosted in a modular microbioreactor equipped with innovative sensing technology and enabling precise control of cell culture conditions. New superparamagnetic biocompatible and biomimetic particles will be used to produce “magnetic cells” to support precise spatiotemporal homing of the cells in the 3D decellularized and bioprinted constructs. The 3D assays will be used to screen the effect of endocrine disruptors (EDs) on the thyroid function in a unique biological sex-specific approach. Their performance will be assessed individually, in comparison with each other, and against in vivo studies. The 3D assays are expected to predict with more sensitivity and specificity the thyroid responses to different classes of EDs at low doses, compared to classical 2D in vitro assays or animal models. Supporting the “Adverse Outcome Pathway” concept, proteogenomics analysis and biological modelling of the underlying mode of action will be used to gain a mechanistic understanding of the chain of events from exposure to adverse effects on thyroid development and function. For future uptake, SCREENED will engage discussion with relevant stakeholder groups, including regulatory bodies and industry, to ensure that the assays are fit for purpose for ED safety assessment
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::d98ce2a7192fd627491c6f773c85dbf9&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::d98ce2a7192fd627491c6f773c85dbf9&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications assignment_turned_in Project2021 - 2026 KCL, KTH, AbbVie, FHG, SIB +23 partnersKCL,KTH,AbbVie,FHG,SIB,KUL,EULAR,STICHTING GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS EU,University of Glasgow,UCD,BMS,UOXF,Universitätsklinikum Erlangen,Atturos,TRAJAN,VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY,NEOTERYX LIMITED,PFIZER,UCB Pharma (Belgium),OXFORD BIODYNAMICS PLC,AMC,UCSC,IDIBAPS-CERCA,University of Manchester,EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH,I-HD,NOVARTIS,REGIONHFunder: EC Project Code: 101007757Overall Budget: 22,978,000 EURFunder Contribution: 10,211,000 EURPsoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal: these represent critical, contemporary unmet clinical needs. HIPPOCRATES is a multi-centre consortium, with 26 world-class partners that have clinical, scientific, data analytics, ethics, patient participation and pharmaceutical industry expertise. We will address these needs. Clinical phenotypic data from multiple established, and de novo PsA cohorts combined with a unique library of bio- samples, images, and data derived therefrom, will be curated and catalogued for optimal evaluation and use. HIPPOCRATES will analyse these multi-structured datasets that traverse the disease timeline, from cutaneous psoriasis, early PsA, first therapeutic and first biologic choice. Through machine learning and other AI techniques, we will: (1) Identify molecular signals associated with the development of PsA in patients with psoriasis, so presaging PsA prevention studies; (2) Create a diagnostic algorithm for early PsA diagnosis in patients with cutaneous psoriasis or early undifferentiated inflammatory arthritis; (3) Generate biomarker algorithms, including clinical, imaging and molecular polyomic moieties, to predict disease progression and identify endotypes permitting precision treatment with existing (methotrexate, and TNF or IL-17 inhibitor) treatments and novel therapeutic regimes; (4) Elucidate the molecular basis of PsA to facilitate future drug discovery; (5) Develop diagnostic digital tools for use in clinical settings. With highly aligned academic/clinical, SME and EFPIA partners, including involvement from existing IMI programmes and competitive international associations, HIPPOCRATES will oversee the development of a sustainable infrastructure to support PsA research and improve PsA patient outcomes.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::598bc93306f2017aa651c1793eb4b839&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euvisibility 24visibility views 24 download downloads 243 Powered bymore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::598bc93306f2017aa651c1793eb4b839&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications and Research data assignment_turned_in Project2020 - 2025 CNR, University of Tübingen, Centre Hospitalier Régional et Universitaire de Lille, BII GMBH, ERASMUS MC +30 partnersCNR,University of Tübingen,Centre Hospitalier Régional et Universitaire de Lille,BII GMBH,ERASMUS MC,University of Ulm,PFIZER,MEDTRONIC INTERNATIONAL TRADING SARL,UCD,UCSC,Novo Nordisk,University of Bristol,CHUV,OBESITY ACTION COALITION INC,METABOLON GMBH,LIPOTYPE,University of Exeter,Third-i bvba,EASO,GU,UCC,Atturos,SIB,KUL,UM,JDRF,GEORGE WASHINGTON UNIVERSITY,AP-HP,DASMAN RESEARCH EDUCATION AND TRAINING COMPANY,University of Dundee,Eli Lilly and Company Limited,T1D EXCHANGE INC,MACCABI HEALTHCARE SERVICES HMO MACCABI,IDIBGI,LUNDS UNIVERSITETFunder: EC Project Code: 875534Overall Budget: 16,668,400 EURFunder Contribution: 8,301,000 EURSOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulations in terms of (a) the risks of complications linked to obesity, (b) response to various obesity treatments. The subpopulations will be characterised in terms of operational variables (phenotypic, genetic, behavioural, environmental, and omics). These predictive variables will facilitate diagnosis and underpin personalised and protocolised obesity care. Patient priorities regarding risk and response will influence all aspects of our work. SOPHIA will create a federated database of premier EU cohorts to identify operational variables that are predictive of risk and treatment response in people with and without diabetes. We will validate the predictive value of these variables before creating clinically-useful algorithms to decide “when-to-treat” and “how-to-treat”. Biomarker variables will feed into innovative assays, tests and research targets. We will interpret and analyse our results, to identify shared value across all stakeholders (patients, clinicians, industry, payers). SOPHIA will change attitudes and experience of obesity by (1) demonstrating the heterogeneity of the disease, (2) identifying people at risk of complications, (3) identifying the best treatment for each individual, (4) delivering a common vocabulary and shared understanding of obesity, (5) demonstrating shared value, which combines commercial opportunity with societal benefit. Our ambition will only be realised if (a) payers agree to fund treatment, (b) industry generate effective treatments, (c) clinicians are prepared to prescribe treatments, and (d) patients are prepared to take treatments. The evidence base does not currently exist. SOPHIA will deliver this evidence and the shared value analysis to drive this revolution in obesity care.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::e7952715c46aaea812010080d3bea125&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euvisibility 67visibility views 67 download downloads 159 Powered bymore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::e7952715c46aaea812010080d3bea125&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu